Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.56 |
| ▸ | KHK | P50053 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 4/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7578338 | 0.92 | EGFR (0.47) | EGFRBRAFHPGDCSNK2A1 | |
| SCHEMBL7578814 | 0.92 | EGFR (0.54) | EGFR | |
| SCHEMBL7578341 | 0.90 | CSNK2A1 (0.52) | EGFRCSNK2A1 | |
| SCHEMBL7586964 | 0.86 | EGFR (0.60) | EGFRSYKKCNH2AURKBBRAF | |
| SCHEMBL7585306 | 0.83 | EGFR (0.56) | EGFRBRAFHPGD | |
| SCHEMBL7588633 | 0.83 | EGFR (0.55) | EGFRSYKKCNH2MAPK3MAPK1 | |
| SCHEMBL8317556 | 0.82 | EGFR (0.67) | EGFRKHKSYKKCNH2MAPK3 | |
| SCHEMBL7578986 | 0.81 | EGFR (0.73) | EGFRSYKKCNH2AURKBBRAF | |
| SCHEMBL7853933 | 0.80 | EGFR (0.49) | EGFRGRIN2B | |
| SCHEMBL7576275 | 0.80 | EGFR (0.52) | EGFRSYKKCNH2MAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082420-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082420-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | PKD1, REN, CYP11B1 | EGFR 1041/4885KHK 4113/4885SYK 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.